• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
Home
  • Research
  • Biotech
    • Clinical Data
    • Venture Capital
    • Deals
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending Topics
    • Cell & Gene Therapy
    • COVID-19
    • Emerging Biopharma
  • Podcasts
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
  • Subscribe
Search Icon
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Research
  • Biotech
    • Clinical Data
    • Venture Capital
    • Deals
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending Topics
    • Cell & Gene Therapy
    • COVID-19
    • Emerging Biopharma
  • Podcasts
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events

Emerging Biopharma

Stop sign
Biotech

Assembly, Context and Innate add to pile of dumped R&D prospects

The latest set of earnings reports brought news of more drug programs that are being stopped or deprioritized.
Nick Paul Taylor Mar 23, 2023 8:00am
money financing funds

Fierce Biotech Fundraising Tracker: Switch, Allorion and more

Mar 22, 2023 11:00am
Liver disease

89bio hits primary goals in midphase NASH trial, plots phase 3

Mar 22, 2023 8:31am
solar flare sun

Flare fires up with $123M series B and 3 Big Pharmas in tow

Mar 22, 2023 6:30am
picture of an individual leaping between boulders

BeiGene lets option on Leap’s immuno-oncology candidate lapse

Mar 17, 2023 8:50am
Graphic of a dollar bill as puzzle pieces

With $105M and Big Pharma backing, Mediar takes aim at fibrosis

Mar 15, 2023 8:21am
More News

Why do so many biotechs face being kicked off the Nasdaq?

Mar 14, 2023 9:55am

UPDATE: SVB failure sends shock waves across biotech industry

Mar 10, 2023 11:31am

Flagship fledging fetches $50M to fire drugs at specific organs

Mar 7, 2023 9:15am

Third Rock, J&J neuroscience spinout Rapport arrives with $100M

Mar 7, 2023 9:05am
See more stories
Home
  • Connect
    • The Team
    • Advertise
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2023 Questex LLC All rights reserved.
Terms of use
Privacy Policy